Overview
- A pooled analysis published in BMJ Open found people starting newer GLP‑1 drugs (semaglutide or tirzepatide) had substantially lower rates of alcohol-related hospital admissions compared with several active comparator drugs.
- Research published in JAMA Pediatrics shows GLP‑1 prescriptions rose sharply for adolescents and young adults since 2022 while bariatric surgery rates in that group fell, prompting calls for more evidence on long-term safety and treatment sequencing.
- U.K. regulators approved the first oral GLP‑1 pill for weight management and the U.S. Centers for Medicare & Medicaid Services launched an 18‑month Medicare demonstration offering GLP‑1 access for $50 a month, with early reports showing many beneficiaries choose injectables.
- Independent reviewers say GLP‑1s are cost‑effective but insurers limit coverage because broad uptake would hit large budgets, and experts warn high early discontinuation rates mean drug use alone may not deliver lasting health or cost savings without bundled lifestyle support.
- Researchers and regulators caution against cheaper compounded or knockoff GLP‑1 products that lack FDA review, and they emphasize unresolved questions about long‑term safety, equity of access, and how to sustain weight loss after treatment stops.